Vitiligo is a chronic autoimmune disease in which the immune system destroys melanocytes — the cells that produce pigment — leaving smooth, depigmented white patches on the skin. It affects roughly 1–2% of people worldwide, can begin at any age, and is often psychologically devastating precisely because it is so visible. It is not contagious, not an infection, and not the result of anything the patient did wrong. It is also not the same condition as melasma or post-inflammatory hyperpigmentation (covered in our melasma treatment guide); those are disorders of too much pigment, while vitiligo is a disorder of pigment loss. The distinction matters because the treatments point in opposite directions.
For most of dermatologic history, the goal of vitiligo treatment was modest: stop the spread and recover some color, knowing that full repigmentation was rare and that the condition often returned. That changed in July 2022, when the FDA approved Opzelura (ruxolitinib) 1.5% cream — the first and so far only FDA-approved pharmacologic treatment to address repigmentation in vitiligo. It did not make vitiligo easy to treat, but it gave the field its first purpose-approved drug. This article covers how Opzelura works, where narrowband UVB and the 308 nm excimer laser still fit, when surgery is appropriate, and what repigmentation realistically looks like. It is educational and not a substitute for care from a board-certified dermatologist.
The mechanism — and why skin of color is central
Vitiligo is driven by interferon-gamma signaling through the JAK-STAT pathway, which recruits CD8+ T-cells that destroy melanocytes. That same JAK axis is why the new topical drug works (see below). Repigmentation — when it happens — comes not from saving dead melanocytes but from coaxing surviving pigment-cell reservoirs, mostly in the hair follicles, to migrate out and re-color the skin. That is the key biological limit of every treatment here: areas without pigmented hairs (the hands, feet, wrists, ankles) repigment poorly, because there is no reservoir to draw from, while the face and neck respond comparatively well. Anyone who promises full repigmentation on the hands is overpromising.
Vitiligo is especially consequential in Fitzpatrick IV–VI (skin of color), where the contrast between depigmented and normally pigmented skin is sharpest and the psychosocial burden highest — a consideration woven through the broader safety and selection guidance in our skin-of-color treatment article. Approaches that work well on lighter skin still work here; the difference is that pigment-stimulating therapies must be pursued consistently and that sun protection matters doubly, both to avoid sunburn of depigmented skin and to prevent the surrounding skin from darkening and widening the visible contrast (a "halo" effect around spots is common in summer).
Opzelura (ruxolitinib) — the first repigmentation drug, approved July 2022
On July 18, 2022, the FDA approved ruxolitinib 1.5% cream (Incyte) for the topical treatment of nonsegmental vitiligo in adults and pediatric patients 12 and older. It is a topical JAK1/JAK2 inhibitor: by dampening the interferon-gamma signaling that drives melanocyte destruction, it quiets the autoimmune attack so that follicular melanocytes can migrate out and repigment the patch. Approval was based on the phase 3 TRuE-V1 and TRuE-V2 trials in 674 patients, in which about 30% of those applying Opzelura twice daily achieved at least a 75% improvement in their facial Vitiligo Area Scoring Index (F-VASI75) at week 24 — versus roughly 8–13% on vehicle (non-medicated) cream — rising to about 50% at week 52.
Three practical points the trials make clear:
- It is applied twice daily to affected areas, up to 10% of body surface area. Larger BSA coverage is not in the label.
- Response is slow and cumulative. Satisfactory repigmentation can require more than 24 weeks of consistent use; the week-52 results were better than week-24, meaning patients who quit early quit before the drug's full benefit.
- It works best on the face. The F-VASI (facial) endpoints were the strongest; total-body and acral (hand/foot) repigmentation are slower and less complete, consistent with the follicular-reservoir biology above.
Opzelura carries the JAK-class boxed warning (serious infections, mortality, malignancy, MACE, thrombosis). Those risks are drawn from oral JAK inhibitors used systemically in older, higher-risk populations; the systemic exposure from a topical cream used within the labeled body-surface-area limit is far lower. Still, it is not meant to be combined with other JAK inhibitors or potent systemic immunosuppressants, and a responsible prescriber screens for active infection and relevant history before prescribing.
Light therapy — the cornerstone that predates the drug
For widespread or rapidly spreading disease, and for many patients who do not respond fully to a topical, phototherapy remains the backbone.
- Narrowband UVB (NB-UVB, 311–313 nm) is the first-line phototherapy for nonsegmental vitiligo, given two to three times weekly. It suppresses the T-cells attacking melanocytes and stimulates surviving melanocyte precursors. It works well on the face, neck, and trunk; efficacy on the hands and feet is poor (repigmentation rates under 30% in those areas). Realistic timeframes are six to twelve months of consistent treatment. NB-UVB is the standard post-surgery phototherapy as well.
- The 308 nm excimer laser (and excimer lamp) is targeted phototherapy — the same UVB biology delivered to individual patches through a handpiece, allowing higher fluence to a small area. It is FDA-cleared for vitiligo and is the choice for localized disease (limited number of patches), typically two to three sessions per week. The Vitiligo Task Force positions it alongside shared decision-making that weighs its cost and accessibility against whole-body NB-UVB.
- Combination therapy works. Excimer plus a topical (a JAK inhibitor, a calcineurin inhibitor, or a vitamin D analog) outperforms either alone — recent reviews report combination protocols pushing repigmentation rates higher, including in stubborn acral lesions.
The catch with all phototherapy is logistics and ceiling effect: it requires repeated in-office (or disciplined home) visits over many months, and it stops working on areas without a pigment reservoir. Repigmentation from phototherapy can also be lost if treatment stops and disease flares again.
Segmental vs. nonsegmental — why the distinction changes the plan
Vitiligo comes in two patterns that behave differently and are treated differently. Nonsegmental vitiligo (NSV) is the common form: slow, symmetrical, bilateral patches that progress over a lifetime, and the form for which Opzelura is approved. Segmental vitiligo (SV) affects a minority of patients (roughly 5–16%), spreads rapidly on one side of the body along a nerve segment, then tends to stabilize and stop. Because SV becomes stable and is often localized, it is a better candidate for surgical repigmentation; because it is unilateral and less driven by systemic autoimmune flaring, whole-body phototherapy and systemic approaches matter less. Knowing which pattern you have — a diagnosis a dermatologist makes clinically — is the first fork in the treatment road.
Topicals beyond Opzelura — and what they do
Before Opzelura, the standard topicals were potent topical corticosteroids (for limited patches, with the usual steroid caveats about thinning skin with prolonged use) and topical calcineurin inhibitors (tacrolimus and pimecrolimus), which are especially useful on the face and neck and around the eyes where steroids are unsafe long-term. Calcineurin inhibitors pair well with phototherapy. One point competitors often gloss over: Opzelura is the only topical whose vitiligo use is FDA-approved; the corticosteroids and calcineurin inhibitors are used off-label — which does not mean they are inappropriate, only that the evidence behind them came from practice and studies rather than a labeled indication. Topical ruxolitinib has not erased these options; it has added to them, and combination strategies are common.
Surgery — for stable, refractory disease
When disease has been stable for at least 6–12 months and patches have not responded to medical therapy, surgical repigmentation can transfer pigment-producing cells from normally pigmented skin into depigmented areas. Techniques include suction-blister epidermal grafting, punch (mini) grafting, and melanocyte-keratinocyte cell suspension transplantation (e.g., the ReCell-type approach), in which a small biopsy is processed into a cell suspension sprayed or spread onto prepared recipient skin. Surgery is not for active, spreading disease — transplanting cells into an active autoimmune battlefield wastes the graft — and it is followed by NB-UVB to stimulate the transferred cells. The selection of technique depends on the size, site, and stability of the patches and the surgeon's expertise.
Depigmentation — when the goal flips, for extensive disease
For the small subset of patients with very extensive vitiligo — more than 50% of body surface area affected — in whom repigmentation is unrealistic, the treatment goal can invert: instead of trying to add color back, the remaining normally pigmented skin is depigmented to produce a uniform, even tone. The agent used is monobenzone (monobenzyl ether of hydroquinone, MBEH), the only drug FDA-approved to induce depigmentation (approved since 1952), typically applied as a 20% cream twice daily, with response usually obtained over one to four months. In a cited study, 20% monobenzone produced depigmentation in 84% of treated patients, complete in 44%.
This is a one-way door and a serious decision. Depigmentation is permanent and irreversible, makes all treated skin permanently sun-sensitive, and is reserved for carefully selected, extensively affected patients who have exhausted repigmentation options and consciously prefer an even depigmented appearance over patchy mixed coloring. It is not a cosmetic skin-lightener and is entirely inappropriate for ordinary pigment concerns. Anyone considering it needs an explicit, unhurried conversation about irreversibility and sun protection with a dermatologist experienced in the technique.
What it costs
Opzelura is a branded specialty cream and can be expensive out of pocket; access usually runs through insurance with prior authorization, and manufacturer copay and assistance programs exist. NB-UVB phototherapy is a series of office visits (or the cost of a home unit), and excimer laser is typically a cash-pay cosmetic-tier course of many sessions. Surgical grafting is a procedural cost. The realistic planning question is staged: what does first-line therapy cost, and what is the next step if it is incomplete?
What to ask a dermatologist
- Is my vitiligo segmental or nonsegmental, and is it stable or spreading? That single distinction shapes everything — drug choice, phototherapy, and whether surgery is even an option.
- Am I a candidate for Opzelura, and what body surface area will I be treating? The label caps coverage at 10% BSA.
- What is the realistic timeline and endpoint for my patches? Face will do better than hands; ask honestly.
- Should I combine the topical with phototherapy? Combination typically outperforms monotherapy.
- What is my sun-protection and camouflage plan? Sunscreen prevents burn and contrast-widening; cosmetic camouflage is a legitimate part of management while waiting for repigmentation.
- Is surgery on the table, and only after my disease has been stable for at least six months? A credible answer treats stability as a hard precondition.
Vitiligo is no longer untreatable. With Opzelura, modern phototherapy, and stable-disease surgery, most patients can recover meaningful color — especially on the face — and stop progression. The patients who do best are the ones who set realistic expectations by body site, treat consistently rather than in bursts, and work with a dermatologist who treats the condition as the chronic autoimmune disease it is.
Sources
- FDA — FDA approves topical treatment addressing repigmentation in vitiligo in patients 12 and older (Opzelura, July 18, 2022): https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older
- Incyte / BioSpace — FDA approval of Opzelura (ruxolitinib) cream for nonsegmental vitiligo; first repigmentation treatment (TRuE-V1/V2 week 24 and week 52 data): https://www.biospace.com/incyte-announces-u-s-fda-approval-of-opzelura-ruxolitinib-cream-for-the-treatment-of-vitiligo
- FDA / accessdata — Opzelura full prescribing information (F-VASI75 endpoints, 10% BSA dosing, boxed warning): https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215309s001lbl.pdf
- PMC — FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy (mechanism, trial design, safety): https://pmc.ncbi.nlm.nih.gov/articles/PMC9486756
- PMC — Recent Advances in Vitiligo Treatment (NB-UVB first-line, acral limits <30%, excimer + JAK combination, IL-15 pipeline): https://pmc.ncbi.nlm.nih.gov/articles/PMC13044860
- MDPI — Excimer lamp vs. NB-UVB vs. 308 nm excimer laser in vitiligo repigmentation (systematic review, 308 nm FDA clearance history): https://www.mdpi.com/2673-6179/5/3/12
- Frontiers in Immunology — Management of the refractory vitiligo patient (surgical options, stability requirement, post-op NB-UVB): https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1294919/full
- UMass — Vitiligo NB-UVB treatment protocol (2–3× weekly, dose titration to mild erythema): https://www.umassmed.edu/globalassets/vitiligo/umass-uvb-phototherapy-guidelines.pdf
- Skin Therapy Letter — Update on the Management of Vitiligo (segmental vs nonsegmental, excimer for <10% BSA, depigmentation thresholds, afamelanotide): https://www.skintherapyletter.com/vitiligo/update-on-management
- Global Vitiligo Foundation — Depigmentation (monobenzone 20% MBEH, 84% response / 44% complete, maintenance dosing): https://globalvitiligofoundation.org/depigmentation
- Managed Healthcare Executive — Key Updates in the Treatment of Patients With Vitiligo (NSV vs SV course, treatment algorithm, Opzelura as sole FDA-approved topical): https://www.managedhealthcareexecutive.com/view/key-updates-in-the-treatment-of-patients-with-vitiligo
